These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 16382111)

  • 1. Flare in neuropathy following rituximab therapy for Waldenstrom's macroglobulinemia.
    Noronha V; Fynan TM; Duffy T
    J Clin Oncol; 2006 Jan; 24(1):e3. PubMed ID: 16382111
    [No Abstract]   [Full Text] [Related]  

  • 2. Severe peripheral neuropathy following carfilzomib, rituximab, and dexamethasone for initial treatment of Waldenström's macroglobulinemia.
    Alfaraj WA; Cachia D; Tummala S; Thomas SK; Manasanch EE
    Ann Hematol; 2016 Jan; 95(2):347-8. PubMed ID: 26432713
    [No Abstract]   [Full Text] [Related]  

  • 3. Case of mononeuritis multiplex onset with rituximab therapy for Waldenström's macroglobulinemia.
    Mauermann ML; Ryan ML; Moon JS; Klein CJ
    J Neurol Sci; 2007 Sep; 260(1-2):240-3. PubMed ID: 17537458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatocellular carcinoma followed by Waldenström's macroglobulinemia: a case report.
    Hasegawa K; Kubota K; Hirai H; Imai Y; Midorikawa Y; Makuuchi M
    Hepatogastroenterology; 2000; 47(33):842-5. PubMed ID: 10919044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proinflammatory syndrome mimicking acute rheumatoid arthritis in a patient with Waldenstrom's macroglobulinemia treated with rituximab.
    Buda-Okreglak EM; Drabick JJ; Delaney NR
    Ann Hematol; 2004 Feb; 83(2):117-9. PubMed ID: 14513285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lenalidomide and rituximab in Waldenstrom's macroglobulinemia.
    Treon SP; Soumerai JD; Branagan AR; Hunter ZR; Patterson CJ; Ioakimidis L; Chu L; Musto P; Baron AD; Nunnink JC; Kash JJ; Terjanian TO; Hyman PM; Nawfel EL; Sharon DJ; Munshi NC; Anderson KC
    Clin Cancer Res; 2009 Jan; 15(1):355-60. PubMed ID: 19118065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effective treatment with rituximab in two patients with Waldenström macroglobulinemia].
    Yoshimi A; Arai S; Iijima K; Iki S; Usuki K; Urabe A
    Rinsho Ketsueki; 2005 Oct; 46(10):1109-13. PubMed ID: 16440772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoglobulin M 'Flare' after rituximab-associated acute tubular necrosis in Waldenström's macroglobulinemia.
    Izzedine H; Bourry E; Amrouche L; Brocheriou I; Uzunov M; Capron F; Leblond V; Deray G
    Int J Hematol; 2009 Mar; 89(2):218-222. PubMed ID: 19156501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble CD27 is a faithful marker of disease burden and is unaffected by the rituximab-induced IgM flare, as well as by plasmapheresis, in patients with Waldenström's macroglobulinemia.
    Ciccarelli BT; Yang G; Hatjiharissi E; Ioakimidis L; Patterson CJ; Manning RJ; Xu L; Liu X; Tseng H; Gong P; Sun J; Zhou Y; Treon SP
    Clin Lymphoma Myeloma; 2009 Mar; 9(1):56-8. PubMed ID: 19362974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Waldenström's macroglobulinemia and bortezomib.
    Leblond V
    Haematologica; 2005 Dec; 90(12):1589A. PubMed ID: 16330427
    [No Abstract]   [Full Text] [Related]  

  • 11. Myelopathy from Waldenström's macroglobulinemia: improvement after Rituximab therapy.
    Liberato B; Riethmuller A; Comenzo RL; Lis E; Raizer JJ
    J Neurooncol; 2003 Jun; 63(2):207-11. PubMed ID: 12825826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An unusual reoccurrence of Waldenstrom's macroglobulinemia as pleural effusions that had a discordant response with treatment.
    Amin CJ; Rabinowitz I
    Clin Lab Haematol; 2005 Jun; 27(3):200-2. PubMed ID: 15938727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study.
    Ghobrial IM; Fonseca R; Greipp PR; Blood E; Rue M; Vesole DH; Gertz MA;
    Cancer; 2004 Dec; 101(11):2593-8. PubMed ID: 15493038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IgM MGUS and Waldenstrom-associated anti-MAG neuropathies display similar response to rituximab therapy.
    Campagnolo M; Zambello R; Nobile-Orazio E; Benedetti L; Marfia GA; Riva N; Castellani F; Bianco M; Salvalaggio A; Garnero M; Ruiz M; Mataluni G; Fazio R; Ermani M; Briani C
    J Neurol Neurosurg Psychiatry; 2017 Dec; 88(12):1094-1097. PubMed ID: 28501820
    [No Abstract]   [Full Text] [Related]  

  • 15. Nervous system dysfunction in Waldenström's macroglobulinemia: response to treatment.
    Rudnicki SA; Harik SI; Dhodapkar M; Barlogie B; Eidelberg D
    Neurology; 1998 Oct; 51(4):1210-3. PubMed ID: 9781565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The International Prognostic Scoring System for Waldenstrom's macroglobulinemia is applicable in patients treated with rituximab-based regimens.
    Dimopoulos MA; Kastritis E; Delimpassi S; Zomas A; Kyrtsonis MC; Zervas K
    Haematologica; 2008 Sep; 93(9):1420-2. PubMed ID: 18641029
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical and immunological worsening in a patient affected with Waldenstrom macroglobulinemia and anti-mag neuropathy after treatment with rituximab.
    Gironi M; Saresella M; Ceresa L; Calvo M; Ferrante P; Merli F; Nemni R
    Haematologica; 2006 Jun; 91(6 Suppl):ECR17. PubMed ID: 16785123
    [No Abstract]   [Full Text] [Related]  

  • 18. Development of nasal skin necrosis associated with rituximab treatment for Waldenström's macroglobulinemia and subsequent spontaneous resolution.
    Pearlman AN; Fechner FP; Constantinides M
    Ear Nose Throat J; 2006 Jul; 85(7):431-3. PubMed ID: 16909812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Peripheral neuropathy in Waldenstrom's macroglobulinemia. Antibody activity of monoclonal immunoglobulin M directed against vimentin].
    Dellagi K; Chedru F; Clauvel JP; Brouet JC
    Presse Med; 1984 May; 13(19):1199-201. PubMed ID: 6326084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in the treatment of Waldenström's macroglobulinemia.
    Johnson SA
    Expert Rev Anticancer Ther; 2006 Mar; 6(3):329-34. PubMed ID: 16503850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.